The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...

New data from a phase IIb trial extension study suggested that investigational neflamapimod led to significant improvements ...

Treatment with neflamapimod slowed clinical worsening and led to reduced disease-related plasma biomarkers in individuals with dementia with Lewy bodies, according to a speaker at CTAD. “Dementia with ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

Please provide your email address to receive an email when new articles are posted on . In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association ...

New research suggests that two proteins, amyloid- and phosphorylated tau, the key proteins of Alzheimer's disease, are detected in blood once symptoms have started in Lewy's body diseases, such as ...

Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational ...

Share on Pinterest A new drug candidate called SAK3 successfully stopped the progression of a form of dementia in mice. Jacek Kadaj/Getty Images A drug candidate called SAK3 prevented further loss of ...

Penn Medicine researchers will advance their understanding of the underlying causes of cognitive decline in individuals with Lewy body diseases, like Parkinson's, and identify biomarkers that predict ...

While Alzheimer’s disease is the most common type of dementia, there’s another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US. It is ...

Alzheimer’s disease is the most commonly diagnosed form of dementia, but it’s far from the only one. In fact, most people who ...

Early detection of Alzheimer’s disease-related changes in Parkinson's disease and dementia with Lewy bodies could be made possible by monitoring the amyloid-β (Aβ) and phosphorylated tau (p-tau) ...